Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Table 2 Frequencies of NK/T-cell Lymphoma, nasal type, and aggressive NK-cellleukemia in previous published series

From: Aggressive mature natural killer cell neoplasms: from epidemiology todiagnosis

Series Origin NKTCL ANKCL NKTCL + ANKCL [References]
NK-cell Tumor Study Group * Asia (Japan) 150 (87.2%) 22 (12.8%) 172 (100%) [37]
Nasal: 123 (82.0%)
Extranasal: 27 (18.0%)
International Peripheral T-Cell Lymphoma Project (IPTCLP)group** North America, Europe, and Asia 127 (98.5%) 2 (1.5%) 129 (100%) [35]
Nasal: 92 (72.4%)
Extranasal: 35 (27.6%)
Brazilian group South America (Brazil) 120 (100%) 0 (0%) 120 (100%) [44]
Nasal: 97 (80.8%)
Extranasal: 23 (19.2%)
Intergruppo Italiano Linfomi Europe (Italy) 26 (100%) 0 (0%) 26 (100%) [39]
Nasal: 23 (88.5%)
Extranasal: 3 (11.5%)
All series 423 (94.6%) 25 (5.6%) 447 (100%) NA
Nasal: 335 (79.4%)
   Extranasal: 88 (20.6%)    
  1. Abbreviations: ANKTCL aggressive NK-cell leukemia,NKTCL NK/T-cell Lymphoma, nasal type, NA notapplicable.
  2. * Most of the cases presented in this series were from the Japanesesurvey of NK-cell neoplasms diagnosed between 1994 and 1998, inwhich 237 cases were registered: 149 nasal-type NK-cell lymphoma(123 nasal and 26 extranasal), 22 aggressive NK-cellleukemia/lymphoma, 19 chronic NK lymphocytosis and 57 casescorresponding to diseases that are not considered as originatingfrom mature NK-cells accordingly to the WHO classification updatedin 2008 (11 myeloid/NK-cell precursor acute leukemia, 15 blasticNK-cell lymphoma, 21 precursor NK-cell acute lymphoblastic leukemia) [36].
  3. ** Consecutive cases of peripheral T-cell lymphoma (excluding MycosisFungoides and Sezary syndrome) and NK/T-cell lymphoma diagnosedbetween 1990 and 2002. Total number of cases registered: 1153 (Asia:464, 40.2%; Europe and North America 689, 59.8%). Totalnumber of NK-cell neoplasms registered: 136 (11.8%) (Asia: 104,76.5%; Europe and North America: 32, 23.5%) (NKTCL: 127;ANKCL: 2; unclassified NK-cell neoplasms: 7).